Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1

por Moshoette, Tumelo, Ali, Stuart Alvaro, Papathanasopoulos, Maria Antonia, Killick, Mark Andrew
Publicado 2019